Melodiol Global Health Limited

Melodiol Q2 Revenue and Updates

Melodiol Global Health Limited (ASX:ME1) (‘Melodiol’ or ‘the Company’) is pleased to advise that it has delivered another strong revenue quarter. During Q2 of 2024, Melodiol generated unaudited revenue of$4.8m, a 9% increase on Q1 2024 ($4.4m). H2 2024 unaudited revenues now total $9.2m, a 31% increase on H1 2023 ($7.0m).

Highlights:

  • Q2 2024 unaudited revenues total $4.8m, a 9% increase on Q1 2024 ($4.4m)
  • Brings H1 2024 unaudited revenues to $9.2m, a 31% increase on H1 2023 ($7.0m)
  • Growth underpinned by strong results at Mernova

Growth was underpinned by strong results at Mernova. During Q2 of 2024, Mernova had confirmed unaudited purchase orders of $2.0m (C$1.8m). This figure is a 25% increase on Q1 2024 ($1.6m) and a 33% increase on Q2 2023 ($1.5m). In addition to these strong results, Mernova already has confirmed purchase orders for Q3 2024 of $452k (C$411k), providing a strong foundation for the quarter.

Additionally, Mernova achieved a variety of key objectives, including the introduction of a new product category (edibles), the approval of numerous new SKUs in existing provinces, the introduction of new vaporiser flavours and a supply agreement to source additional capacity to keep up with strong demand.

In addition to these strong results, Mernova already has confirmed purchase orders for Q3 2024 of $452k (C$411k), providing a strong foundation for the quarter.

During Q2 of 2024, HHI also provided $2.8m in sales between its Australian and UK divisions. As stated previously, the Company is committed to rationalising non-core business units, while focusing on its core divisions, Mernova and HHI in an effort to achieve profitability as quickly as possible.

Management commentary:

CEO and Managing Director, Mr William Lay said:“We are very pleased to demonstrate quarter on quarter growth for Melodiol as a group. During the last year, the Company has completed a step change in terms of revenue size, and we are sharply focused on Mernova and HHI as our core business units. By focusing on these business units, and rationalising non-core business units, all of our teams are working hard to achieve group profitability as quickly as possible.”


Click here for the full ASX Release

This article includes content from Melodiol Global Health, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

ME1:AU
The Conversation (0)
Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

Highlights:

  • 6-week top-line data from Part A of COMP005 phase 3 trial in treatment resistant depression on track for late June
  • Phase 3 COMP006 in TRD on track for 26-week data second half of 2026
  • Cash position of $260.1 million at March 31, 2025
  • Conference call on May 8 at 8:00 am ET (1:00 pm UK)

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

COMPASS Pathways Plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in underserved communities, if FDA approved. This agreement with HealthPort expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with treatment resistant depression (TRD) receive their care in the United States.

HealthPort offers an integrated model of care aimed at helping those with behavioral health conditions and people impacted by poverty, disability and trauma. HealthPort is an evidence-based practice supporting thirteen dimensions of social determinants of health, including the coordination of an integrated outpatient mental health and addictions health clinic. HealthPort has been operating facility, residential, and mobile based interventions of care in the lower Eastern Shore of Maryland for the past 45 years.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

Compass management will host a conference call at 8:00 am ET (1:00 pm UK)

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Highlights:

  • Participants received a single dose of either 25 mg of COMP360 or placebo
  • On track for disclosure of top-line 6-week primary endpoint results in late June

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Highlights:

  • Screening closed for all sites and final participants being scheduled for dosing
  • On track for top-line 6-week primary endpoint results in late Q2

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Highlights:

  • 52-week observational follow-up study from Phase 2b reveals single 25 mg COMP360 psilocybin dose offers longer-term antidepressant effects compared to lower doses, with average efficacy for a single dose of 25mg lasting about 12 weeks and substantially longer in a subgroup
  • Findings published in the March edition of the Journal of Clinical Psychiatry

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×